Hutchison China Meditech Limited: Change of Non-Executive

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Hutchison China Meditech Limited: Change of Non-Executive Directors

HONG KONG, CHINA--(Marketwired - Aug 2, 2016) - Hutchison China Meditech Limited ( NASDAQ : HCM )

Nasdaq: HCM

Change of Non-executive Directors

London: Tuesday, August 2, 2016: Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM) today announces with effect from August 1, 2016, Dr Dan Eldar has been appointed as a Non-Executive Director of Chi-Med in place of Mr Salbaing who has tendered his resignation to spend more time on his existing responsibilities within the CK Hutchison Holdings Group.

Dr Eldar (formerly Perlmutter), aged 63, has more than 35 years of experience as a senior executive, leading global operations in telecommunications, water, biotech and healthcare. He is an executive director of Hutchison Water Israel Ltd which focuses on large scale projects including desalination, wastewater treatment and water reuse. He is also an independent non-executive director of Leumi Card, a subsidiary of Bank Leumi Le-Israel B.M., one of Israel's leading credit card companies. Further, he is also a director of Aqua Blue Water Management Services Ltd, Hutchison Biofilm Medical Solutions Holdings Limited, Hutchison Biofilm Medical Solutions Inc., Hutchison Biofilm Medical Solutions Limited, Hutchison Biofilm Solutions Limited, Hutchison Water General Partner Ltd, Hutchison Water Israel E.P.C. Ltd, TACount Exact Ltd and Yissumim Advanced Management Application Ltd. Dr Eldar was previously a director of WeFindTech Ltd. and Gryphonel Ltd within the past five years.

Dr Eldar holds a Doctor of Philosophy degree in Government from Harvard University, Master of Arts degree in Government from Harvard University, Master of Arts degree in Political Science and Public Administration from Hebrew University of Jerusalem and a Bachelor of Arts degree in Political Science from Hebrew University of Jerusalem.

He does not have any shareholdings in Chi-Med. Save for the information disclosed above, there is no other information in relation to Dr Eldar required to be disclosed pursuant to Rule 17 and Schedule 2(g) of the AIM Rules for Companies.

Mr Christian Hogg, Chief Executive Officer of Chi-Med said "We thank Mr Salbaing for his invaluable contributions during his tenure and welcome Dr Eldar to the Board whose experience in the global high tech and biotech industries will be important to Chi-Med."

NOTES TO EDITORS

About Chi-Med

Chi-Med is an innovative China-based biopharmaceutical company which researches, develops, manufactures and sells pharmaceuticals and healthcare products. Its Innovation Platform, Hutchison MediPharma Limited, focuses on discovering and developing innovative therapeutics in oncology and autoimmune diseases for the global market. Its Commercial Platform manufactures, markets, and distributes prescription drugs and consumer health products in China.

Chi-Med is majority owned by the multinational conglomerate CK Hutchison Holdings Limited (SEHK: 0001). For more information, please visit: www.chi-med.com .

 Forward-Looking Statements

This announcement contains forward-looking statements within the meaning of the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect Chi-Med¡¦s current expectations regarding future events. Forward-looking statements involve risks and uncertainties. Such risks and uncertainties include, among other things, the risk that current or future appointees to Chi-Med's board of directors are not effective in their respective positions, the difficulty in locating and recruiting suitable candidates for its board of directors and the management difficulties which may arise from changes in Chi-Med's board of directors. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. For further discussion of these and other risks, see Chi-Med's filings with the U.S. Securities and Exchange Commission and on AIM. Chi-Med undertakes no obligation to update or revise the information contained in this announcement, whether as a result of new information, future events or circumstances or otherwise.

CONTACTS

Investor Enquiries        
Christian Hogg, CEO   +852 2121 8200    
         
International Media Enquiries        
Anthony Carlisle, Citigate Dewe Rogerson   +44 7973 611 888 (Mobile)   anthony.carlisle@cdrconsultancy.co.uk
         
U.S. Based Media Enquiries        
Brad Miles, BMC Communications   +1 (917) 570 7340 (Mobile)   bmiles@bmccommunications.com
         
Susan Duffy, BMC Communications   +1 (917) 499 8887 (Mobile)   sduffy@bmccommunications.com
         
Investor Relations        
Brian Korb, The Trout Group   +1 (917) 653 5122 (Mobile)   bkorb@troutgroup.com
         
David Dible, Citigate Dewe Rogerson   +44 7967 566 919 (Mobile)   david.dible@citigatedr.co.uk
         
Panmure Gordon (UK) Limited        
Richard Gray / Andrew Potts   +44 (20) 7886 2500    

Contacts: RNS Customer Services 0044-207797-4400 rns@londonstockexchange.com http://www.rns.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

BETR's Slide: Investors Face Big Losses, Leadership Shift

Updated Category News Views 206

BETR Investors Left in the Lurch It's a real trainwreck, folks. Better Home & Finance Holding Company, trading under NASDAQ:BETR, is in the spotlight for all the wrong reasons. The company expanded the class period for its investor lawsuit to include even more dates between March and August 2026, reflecting a torturous ride for shareholders. Their stock cratered by a...

Continue Reading
Novo's Research Unlocks New Insights into Food Noise

Updated Category News Views 376

Unpacking the Science Behind Food Noise When folks think about losing weight, most picture shedding pounds and fitting into those elusive smaller jeans. But get this—there’s a curveball called ‘food noise’ that’s making waves in obesity treatment. Novo Nordisk’s semaglutide injections are shaking things up, cutting down on those persistent thoughts about food....

Continue Reading
WeaveGrid Powers EVConnectNC: Charging Incentives Launched

Updated Category News Views 177

Transforming Utilities with EVConnectNC In a fresh move by WeaveGrid, North Carolina's Electric Cooperatives have teamed up to roll out EVConnectNC. This innovative program aims to manage the burgeoning demand for electric vehicle (EV) charging in rural and suburban areas under North Carolina's cooperative umbrella. Think of it as a smart way to handle new loads without...

Continue Reading
Lilly's Obesity Breakthroughs: A Step Beyond the Scale

Updated Category News Views 243

Pushing the Boundaries of Obesity Treatment Alright, let's cut through the noise and get to what really matters here. Eli Lilly is taking on obesity treatment like it's Clash of the Titans at this year's ObesityWeek 2026 in Washington, D.C. Forget just dropping pounds—Lilly wants to reshape how we think about obesity entirely. They're not just leaning into the scale,...

Continue Reading
Webull Faces Class Action: Key Details for Investors

Updated Category News Views 254

What's Really Going on With Webull? When you hear there's a class-action lawsuit brewing, you know something's gone real sideways. Webull Corporation (NASDAQ: BULL) finds itself neck-deep in a securities fraud class action alleging some dicey dealings with China. If you've got skin in the game—and if you bought Webull stock between April 26, 2025, and October 6,...

Continue Reading
Servier's Data on Tovorafenib Shows Promise in pLGG

Updated Category News Views 433

New Light on a Critical Challenge Talk about a fight in the dark. Pediatric low-grade glioma (pLGG) is a menace that families dread, an uphill battle with odds that feel relentless. Enter Servier and its four-year updated data on OJEMDA® (tovorafenib), a beacon of hope for kids battling these tricky brain tumors. Results, presented at the SNO meeting, are fresh off the...

Continue Reading
El Pollo Loco Faces Class Action Over Wage Practices

Updated Category News Views 407

Alright, here's where things start sizzling—El Pollo Loco, the fast-food chicken chain whose name translates to 'The Crazy Chicken'—is in a legal pickle. The lawsuit hanging over their heads could spell a sticky situation for them and possibly ripple through the fast-food industry. The suit, filed by the steadfast firm Blumenthal Nordrehaug Bhowmik De Blouw LLP, has...

Continue Reading
HONGQI's EHS4 Launch in Europe: Bridging East and West

Updated Category News Views 168

Revving Up a New Chapter: HONGQI in Venice There's a new player in the European automotive scene, and it's rolling in with more style than a Venetian gondola. HONGQI, a name that's been turning gears in China since '58, is packing its suitcases full of Eastern elegance and landing straight in Venice with the all-electric EHS4. On November 16, the brand is set to unveil...

Continue Reading
Novo's CagriSema Trial Shows Promising Obesity Results

Updated Category News Views 392

Novo's Latest Weight Loss Gamble Well, look what we have here. Novo Nordisk is shaking up the obesity treatment scene with some bold numbers from their REDEFINE 9 trial. The investigational CagriSema combo of amylin analog and GLP-1 receptor agonist has churned out an eyeball-popping near 21% weight loss. For context, we're staring down the barrel of numbers far meatier...

Continue Reading
Advanta's Game-Changer: Acquiring Misr Hytech to Expand in Africa

Updated Category News Views 338

Advanta's Strategic Move into Africa Alright, let's cut to the chase. Advanta is making a big splash with its acquisition of Misr Hytech, a move that's going to shake things up in Africa's agricultural sector. This isn't just another merger to gloss over with your morning coffee. We're talking about a deal that's supposed to wrap up by January 31, 2027, bringing together...

Continue Reading

Top 5 Most Recently Viewed Articles

Viatris Launches Cash Tender Offers for Outstanding Notes

Updated Category News Views 56

Viatris Launches Cash Tender Offers for Outstanding Notes Viatris Inc. (NASDAQ: VTRS), a leading player in the global healthcare sector, has initiated tender offers to acquire certain outstanding notes. This move is designed to strengthen its financial framework and enhance returns for its shareholders. Notably, the offers include various senior notes that were originally...

Continue Reading
Coke Florida Launches Joyful Holiday Caravan Across Florida

Updated Category News Views 239

Coke Florida Kicks Off Holiday Spirit with Caravan Tour Coca-Cola Beverages Florida, LLC (Coke Florida) is thrilled to share that its beloved annual "Holiday Caravan" is set to return. This event, which has become an essential part of the holiday season, features the iconic Coca-Cola red delivery truck decked out in festive cheer. Families will enjoy complimentary samples...

Continue Reading
Nexxen to Join RBC Conference, Share Insights on Technology

Updated Category News Views 68

Nexxen's Upcoming Participation at RBC Global Conference Nexxen International Ltd. (AIM/NASDAQ: NEXN), a leading global advertising technology platform, is geared up to take part in a significant event, the RBC Global Technology, Internet, Media and Telecommunications Conference. This event provides a stellar opportunity for companies to connect with investors and share...

Continue Reading
GayVeterans.us Obtains 501(c)(3) Status to Broaden Support

Updated Category News Views 125

GayVeterans.us Achieves 501(c)(3) Tax Exempt Status GayVeteransUS-Inc. has recently been granted 501(c)(3) tax-exempt status, marking a significant milestone for the organization. This designation enables supporters to make tax-deductible contributions, strengthening the community's ability to provide enhanced resources and support. The dedication of veteran volunteers...

Continue Reading
Virbac Expands Portfolio with Acquisition of Felanorm Solution

Updated Category News Views 130

Virbac Enhances Its Offerings with Felanorm Acquisition Virbac has announced a significant acquisition that marks a pivotal moment in its commitment to improving the health and quality of life for senior cats. This globally recognized drug is aimed at treating feline hyperthyroidism, a condition that is becoming increasingly common in older cats. Understanding Feline...

Continue Reading